Trichy Daily

Triple Negative Breast Cancer (TNBC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Triple Negative Breast Cancer (TNBC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

December 15
14:49 2020
Triple Negative Breast Cancer (TNBC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Triple Negative Breast Cancer (TNBC) Market

(Albany, US) DelveInsight has launched a new report on “Triple Negative Breast Cancer (TNBC) – Market Insights, Epidemiology, and Market Forecast-2030 

DelveInsight’s “Triple Negative Breast Cancer (TNBC) – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Triple Negative Breast Cancer (TNBC), historical and forecasted epidemiology as well as the Triple Negative Breast Cancer (TNBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the facts:

  • Market Size of TNBC in the 7MM was found to be 438 Million in 2017.
  • As per breastcancer.org, about 70% of breast cancers diagnosed in people with an inherited BRCA mutation, particularly BRCA1, are triple-negative.
  • As per several secondary sources, it can be concluded that TNBCs are significantly larger and of higher grade, but less likely to have lymph node metastases than non-TNBCs.
  • Total Diagnosed Incident cases of Triple Negative Breast Cancer in the 7MM countries was 99,380 in 2017.
  • DelveInsight has also estimated the Sub-type specific cases of TNBC, which are ER-, PR- and HER2- .
  • In the United States, there were 4,793 cases of HER2-TNBC, followed by PR- and ER- sub-types.

 

Request for free Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

Scope of the Report:

  • The report covers the descriptive overview of Triple Negative Breast Cancer (TNBC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Triple Negative Breast Cancer (TNBC) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Triple Negative Breast Cancer (TNBC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Triple Negative Breast Cancer (TNBC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Triple Negative Breast Cancer (TNBC) market

 

Request for free Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

Triple Negative Breast Cancer (TNBC) is defined as the heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

TNBCs are frequently identified as hyper dense masses without associated calcifications. The majority of TNBCs are histologically classified as high-grade, invasive, ductal carcinomas of no special type with basal-like features. Central necrosis, pushing tumor borders, a conspicuous lymphocytic infiltrate, and fibrosis are common histologic features.

TNBC is characterized by various aggressive clinical pathologic features including onset at a younger age, higher mean tumor size, higher-grade tumors, and a higher rate of node positivity. Overall, TNBCs show an aggressive phenotype with a shorter time to relapse and metastatic disease than the more common hormone-receptorepositive invasive ductal carcinomas.

TNBC frequently metastasizes to the viscera, liver, lung or brain. However, this is not always the case as it may also have an oligometastatic phenotype closer to ER+ BC, with only lymph node and bone disease. TNBC is also heterogeneous in terms of time of recurrence. TNBC has a higher rate of recurrence in the first 5 years and a lower rate of recurrence afterwards. The pattern of late recurrence is generally associated with less aggressive disease, frequently with bone metastases.

Request for free Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

Some of the TNBC Companies:

  • Merck
  • Hoffmann-La Roche
  • Infinity Pharmaceuticals
  • CytoDyn
  • Treadwell Therapeutics
  • And Many Others

 

Triple Negative Breast Cancer Drugs Covered:

  • Pembrolizumab
  • Ipatasertib
  • IPI-549
  • Leronlimab (PRO 140)
  • CFI-400945
  • And Many Others

 

Request for free Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

Table of Contents:

1. Key Insights

2. Executive Summary of Triple Negative Breast Cancer (TNBC)

3. Competitive Intelligence Analysis for Triple Negative Breast Cancer (TNBC)

4. Triple Negative Breast Cancer (TNBC): Market Overview at a Glance

4.1. Triple Negative Breast Cancer (TNBC) Total Market Share (%) Distribution in 2017

4.2. Triple Negative Breast Cancer (TNBC) Total Market Share (%) Distribution in 2030

5. Triple Negative Breast Cancer (TNBC): Disease Background and Overview

6. Patient Journey

7. Triple Negative Breast Cancer (TNBC) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Triple Negative Breast Cancer (TNBC) Treatment and Management

8.2. Triple Negative Breast Cancer (TNBC) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Triple Negative Breast Cancer (TNBC) Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Triple Negative Breast Cancer (TNBC): Seven Major Market Analysis

13.1. Key Findings

13.2. Triple Negative Breast Cancer (TNBC) Market Size in 7MM

13.3. Triple Negative Breast Cancer (TNBC) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Triple Negative Breast Cancer (TNBC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

Related Reports:

  • Triple Negative Breast Cancer (TNBC) – Market Insight, Epidemiology and Market Forecast – 2027
  • Triple Negative Breast Cancer (TNBC) – Market Insight, Epidemiology and Market Forecast – 2028
  • Triple Negative Breast Cancer (TNBC) – Pipeline Insights, 2020
  • Triple Negative Breast Cancer (TNBC) – Epidemiology Forecast to 2030
  • Triple-refractory Multiple Myeloma – Market Insight, Epidemiology and Market Forecast – 2030
  • Metastatic triple-negative breast cancer (mTNBC)- Market Insight, Epidemiology and Market Forecast – 2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market

Related Articles